

Date: July 21, 2026

To,
Sr. General Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

BSE Scrip Code: 544319

To,
Sr. General Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

NSE Symbol: SENORES

Dear Sir/Madam,

Sub.: Intimation of Board Meeting scheduled to be held on Monday, July 27, 2026

Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that a meeting of the Board of Directors of Senores Pharmaceuticals Limited (the “Company”) is scheduled to be held on Monday, July 27, 2026 inter alia, to:

1. Consider and approve the Unaudited Consolidated and Standalone Financial Results of the Company for the quarter ended June 30, 2026; and
2. To transact other business matters.

Further, in this connection, please refer our earlier intimation dated June 26, 2026, whereby, pursuant to the Company’s Code of Conduct framed in accordance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 as amended (“the Code”), the Trading Window for dealing in securities of the Company, for persons specified under the Code, was closed from July 01, 2026 till 48 hours after the Unaudited Consolidated and Standalone Financial Results of the Company for the quarter ended June 30, 2026 are approved by the Board of Directors and submitted to Stock Exchanges.

You are requested to take the same on record.

Thanking you.

For Senores Pharmaceuticals Limited

Deval Rajnikant Shah
Whole-Time Director & CFO
DIN: 00332722

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com
W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263